Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform

Area of Science:

• Biotechnology
• Molecular Diagnostics
• Personalized Medicine

Background:

• Routine clinical diagnostics require sensitive and precise molecular detection platforms.
• Existing digital PCR (dPCR) systems can be complex and time-consuming for widespread clinical use.
• There is a need for integrated, user-friendly dPCR solutions for precision cancer monitoring.

Purpose of the Study:

• To develop and validate a novel, fully integrated digital PCR (dPCR) platform for routine clinical diagnostics.
• To demonstrate the platform's capability in detecting and quantifying rare cancer genetic mutations.
• To showcase the utility of the platform for precision cancer monitoring and therapy response tracking.

Main Methods:

• Development of a novel dPCR platform integrating off-the-shelf reagents, microfluidic consumables, and a single instrument.
• Detection and quantification of non-small cell lung carcinoma (NSCLC) EGFR T790M mutants using cell-free DNA (cfDNA) standards.
• Validation of a chronic myeloid leukemia (CML) BCR-ABL1 assay down to 0.01% mutant allele frequency.
• Application of a patient-specific assay for juvenile myelomonocytic leukemia (JMML) to track therapy response.

Main Results:

• The integrated dPCR platform demonstrated a simplified workflow with rapid time-to-answer, minimal sample waste, and low cross-contamination risk.
• Precise detection and quantification of rare EGFR T790M mutants in NSCLC were achieved.
• The platform successfully validated the BCR-ABL1 assay for chronic myeloid leukemia (CML) down to 0.01% mutant allele frequency.
• The JMML assay demonstrated precise tracking of patient response to therapy, achieving complete molecular remission.

Conclusions:

• The novel, fully integrated dPCR platform offers a flexible and powerful solution for routine clinical diagnostics and precision cancer monitoring.
• This technology has the potential to significantly advance personalized medicine by enabling sensitive detection and tracking of cancer recurrence.
• The platform's ease of use and efficiency make it suitable for widespread adoption in clinical settings.